InvestorsHub Logo
Followers 30
Posts 2792
Boards Moderated 0
Alias Born 12/05/2021

Re: flipper44 post# 677454

Saturday, 03/09/2024 8:23:43 AM

Saturday, March 09, 2024 8:23:43 AM

Post# of 693452

This may come as a surprise, but BP do better financially if they buy brilliant small companies on the cheap after the small brilliant companies have their market cap beaten to a fricking pulp.

complete and utter nonsense.

Big Pharmaceutical companies have an interest in paying large amounts for successful nonrevenue biotech. The reason for that is with a large amount paid they can justify charging large amounts for the treatment they bought. They can use the argument with insurance companies and governments that they need to return their investment on the purchased treatment developed by the acquired nonrevenue biotech (hey drug development is expensive). This will increase their profit per share and ultimately then jump the stock price, whereas the purchased price for the nonrevenue biotech sits on the asset side of the large pharmaceuticals balance sheet not impacting operational profit.

A good example is Gilead Sciences acquiring Immunomedics for $21 billion which has led to a much higher treatment price for Trodelvy
https://www.gilead.com/news-and-press/press-room/press-releases/2020/9/gilead-sciences-to-acquire-immunomedics
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News